Antibe Therapeutics Inc.
TSX:ATE.TO
0.295 (CAD) • At close April 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 9.713 | 9.987 | 9.539 | 8.51 | 9.054 | 4.437 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.099 | 6.163 | 6.098 | 5.989 | 5.135 | 5.121 | 2.381 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.099 | 3.55 | 3.889 | 3.55 | 3.375 | 3.934 | 2.056 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.365 | 0.389 | 0.372 | 0.397 | 0.434 | 0.463 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.308 | 14.358 | 13.427 | 8.077 | 3.943 | 2.742 | 0.701 | 0.407 | 2.302 | 1.228 | 0.263 | 0.214 |
| General & Administrative Expenses
| 8.907 | 10.963 | 11.188 | 8.765 | 7.857 | 3.538 | 6.549 | 3.785 | 1.849 | 1.342 | 0.756 | 0.728 |
| Selling & Marketing Expenses
| 0.331 | 0.208 | 2.719 | 3.792 | 3.521 | 3.381 | 1.541 | 0.202 | 0.053 | 0.072 | 0 | 0 |
| SG&A
| 9.238 | 11.171 | 13.907 | 12.557 | 11.378 | 6.92 | 8.089 | 3.987 | 1.902 | 1.414 | 0.756 | 0.728 |
| Other Expenses
| 0 | 0 | 0.478 | 0.572 | 0.416 | 0.377 | 0.353 | 0.838 | 0.217 | 0.029 | 0 | 0 |
| Operating Expenses
| 20.546 | 25.529 | 27.812 | 21.206 | 15.738 | 10.039 | 9.143 | 5.232 | 4.421 | 2.671 | 1.019 | 0.942 |
| Operating Income
| -20.546 | -25.529 | -24.714 | -18.917 | -12.188 | -6.664 | -5.209 | -3.282 | -4.421 | -2.686 | -1.045 | -0.942 |
| Operating Income Ratio
| 0 | 0 | -2.544 | -1.894 | -1.278 | -0.783 | -0.575 | -0.74 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.09 | 0.279 | -0.288 | -1.631 | -0.095 | 0.12 | -0.071 | 0.005 | 0.02 | -0.009 | 0.026 | 0 |
| Income Before Tax
| -19.291 | -25.25 | -24.734 | -19.349 | -12.682 | -7.705 | -6.111 | -3.496 | -4.401 | -2.68 | -1.045 | -0.942 |
| Income Before Tax Ratio
| 0 | 0 | -2.546 | -1.937 | -1.329 | -0.905 | -0.675 | -0.788 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.161 | -0.195 | 1.803 | -0.007 | 0.134 | -0.275 | -0.365 | -0.865 | 0 | -0.015 | 0.026 | 0 |
| Net Income
| -19.475 | -25.055 | -26.301 | -19.342 | -12.816 | -7.43 | -5.746 | -2.631 | -4.401 | -2.68 | -1.045 | -0.942 |
| Net Income Ratio
| 0 | 0 | -2.708 | -1.937 | -1.344 | -0.873 | -0.635 | -0.593 | 0 | 0 | 0 | 0 |
| EPS
| -0.37 | -0.49 | -0.71 | -0.71 | -0.6 | -0.49 | -0.6 | -0.42 | -1.19 | -1.02 | -0.4 | -0.36 |
| EPS Diluted
| -0.37 | -0.49 | -0.71 | -0.71 | -0.6 | -0.49 | -0.6 | -0.42 | -1.19 | -1.02 | -0.4 | -0.36 |
| EBITDA
| -19.193 | -25.148 | -23.732 | -16.646 | -11.74 | -6.27 | -4.852 | -3.015 | -4.401 | -2.665 | -1.019 | -0.942 |
| EBITDA Ratio
| 0 | 0 | -2.443 | -1.667 | -1.231 | -0.737 | -0.536 | -0.68 | 0 | 0 | 0 | 0 |